UNICREDIT BANK/CALL/ASTRAZENECA/12500/0.1/18.09.24 | Real-time Bid/Ask 02:57:08 2024-05-21 EDT | ||
| 0.53 EUR / 0.59 EUR | -1.75% |
|
| Current month | -8.06% | ||
| 1 month | +119.23% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 24-05-20 | 0.57 | -5.00% |
| 24-05-17 | 0.6 | -4.76% |
| 24-05-16 | 0.63 | -4.55% |
| 24-05-15 | 0.66 | -9.59% |
| 24-05-14 | 0.73 | -1.35% |
Delayed Quote Börse Stuttgart
Last update May 20, 2024 at 02:43 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HD137V |
| ISIN | DE000HD137V5 |
| Date issued | 2023-12-04 |
| Strike | 12,500 p |
| Maturity | 2024-09-18 (121 Days) |
| Parity | 10 : 1 |
| Emission price | 0.25 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.84 € |
|---|---|
| Lowest since issue | 0.037 € |
| Spread | 0.05 € |
| Spread % | 8.47% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
153.7
USD
Average target price
167.9
USD
Spread / Average Target
+9.24%
- Stock Market
- Warrants
- Warrant
